ArticleJournal of neuro-oncology2018
Efficacy and safety of Levetiracetam vs. other antiepileptic drugs in Hispanic patients with glioblastoma.
Article in Journal of neuro-oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07072624 (Assessing Phenytoin and Levetiracetam Efficacy, Cost-Effectiveness, and CYP2C9/SV2A Polymorphism in Early Post-Traumatic Seizures), which is not on this map. Cited by 20 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Assessing Phenytoin and Levetiracetam Efficacy, Cost-Effectiveness, and CYP2C9/SV2A Polymorphism in Early Post-Traumatic Seizures: A Multicentric Prospective Randomized Trial
Who cites it
20 citing papers in PubMed, 4 syntheses or guidelines pooled it, 43 citations in OpenAlex.
- Impact of levetiracetam use in glioblastoma: an individual patient-level meta-analysis assessing overall survival.Neurosurgical review · 2024Pooled it
- Movement disorders associated with antiseizure medications: A systematic review.Epilepsy & behavior : E&B · 2022Pooled it
- The effect of levetiracetam treatment on survival in patients with glioblastoma: a systematic review and meta-analysis.Journal of neuro-oncology · 2022Pooled it
- Management of epilepsy in brain tumors.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2019Guideline
- Antiepileptic Drugs for De Novo Seizure Prevention After Craniotomy: A Systematic Review and Network Meta-Analysis of Current Evidence.Journal of clinical medicine · 2025Review
- Association between Levetiracetam Use and Survival in Patients with Glioblastoma: A Nationwide Population-Based Study.Cancer research and treatment · 2025Article
- Epilepsy in Patients with Gliomas.Neurologia medico-chirurgica · 2024Review
- Seizure control by adding on other anti-seizure medication on seizure during levetiracetam administration in patients with glioma-related epilepsy.BMC cancer · 2023Article
- Antitumor Potential of Antiepileptic Drugs in Human Glioblastoma: Pharmacological Targets and Clinical Benefits.Biomedicines · 2023Review
- Quantitative measurement of peritumoral concentrations of glutamate, N-acetyl aspartate, and lactate on magnetic resonance spectroscopy predicts glioblastoma-related refractory epilepsy.Acta neurochirurgica · 2022Article
- Article
- Brain tumor related epilepsy: pathophysiological approaches and rational management of antiseizure medication.Neurological research and practice · 2022Review
- Epilepsy treatment in neuro-oncology: A rationale for drug choice in common clinical scenarios.Frontiers in pharmacology · 2022Review
- Efficacy of antiepileptic drugs in glioma patients with epilepsy: a systematic review.Neuro-oncology practice · 2021Review
- How about Levetiracetam in Glioblastoma? An Institutional Experience and Meta-Analysis.Cancers · 2021Article
- Review
- Geographic disparities in access to glioblastoma treatment based on Hispanic ethnicity in the United States: Insights from a national database.Journal of neuro-oncology · 2020Article
- Clinical Diagnosis and Perioperative Management of Glioma-Related Epilepsy.Frontiers in oncology · 2020Review
- Effect of anti-epileptic drugs on the survival of patients with glioblastoma multiforme: A retrospective, single-center study.PloS one · 2019Article
- Tumor-related epilepsy: epidemiology, pathogenesis and management.Journal of neuro-oncology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 10 institutions in 3 countries.
Funding
Abstract
Epilepsy is a common symptom in patients with glioblastoma (GB). 213 patients with GB from RedLANO follow-up registry were included. All patients underwent surgery, if feasible, followed by chemoradiation based on temozolomide (Stupp platform). Information was recorded regarding demographics, seizure timing, anti-epileptic drugs (AEDs), dosage, time to next seizure, total seizures in 6 months, and main side effects of AEDs. The relationship between epilepsy treatment and overall survival (OS) was evaluated. Mean age was 53 years old and 56.8% were male. Seventy-eight patients (37%) were treated with levetiracetam (LEV), 27% were given another AED and 36% did not require any AED. Choice of AED was not associated with age (p = 0.67), performance status (p = 0.24) or anatomic tumor site (p = 0.34). Seizures and AED requirement were greater in those having primary GB (p = 0.04). After starting an AED, the mean time until next crisis was 9.9 days (SD ± 6.3), which was shorter in those receiving LEV (p = 0.03); mean number of seizures during the first 3 and 6 months were 2.9 and 4, respectively. Most patients treated with LEV (n = 46) required less than two medication adjustments compared to those treated with other AEDs (p = 0.02). Likewise, less patients exposed to LEV required a coadjuvant drug (p = 0.04). Additionally, patients receiving LEV had significantly less adverse effects compared to patients treated with another AED. OS was significantly higher in the group treated with LEV compared to other AEDs (25.5 vs. 17.9 months; p = 0.047). Patients treated with LEV had better seizure control and longer OS compared to other AEDs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.